Share
Summarize with AI
Key takeaways
Regulatory Status: Not FDA-approved for human use. Adipotide has no approved indication, no compounding classification, and no legal pathway for human use in the United States. As of April 2026, it is not on the FDA's 503A compoundable substances list. Research Stage: Extensive preclinical literature and one primate study; no completed, published human efficacy trials as of April 2026. A company-sponsored Phase 1 oncology trial was announced in 2012 but produced no peer-reviewed published results. Availability: Not legally marketed for human use. Superpower does not offer this substance. What it is: A peptidomimetic composed of a white-adipose-tissue-homing sequence fused to a mitochondria-disrupting proapoptotic domain, studied for targeted fat-cell death via vascular ablation. What the evidence actually shows: Robust preclinical weight loss in rodent and primate models, accompanied by a dose-dependent kidney toxicity signal that has not been characterized in humans. PubChem CID 163360068.
Where adipotide comes from and how it works
Origin and discovery
Adipotide originated in the laboratory of Renata Pasqualini and Wadih Arap at the M.D. Anderson Cancer Center. The foundational work was a 2004 Nature Medicine paper by Kolonin, Saha, Chan, Pasqualini, and Arap that used phage-display technology to screen for peptide sequences homing to white adipose vasculature in obese mice. The approach builds on an earlier 1999 proof-of-concept by Ellerby, Arap, Ellerby, and colleagues, also in Nature Medicine, which demonstrated that a vascular-homing peptide could be coupled to a proapoptotic effector domain to kill targeted endothelial cells. Adipotide is the direct application of that architecture to the vasculature of fat tissue. The broader phage-display methodology that underpinned the discovery was formalized in a 2002 Nature Medicine paper by Arap, Kolonin, Trepel, and colleagues that laid out the platform for mapping the human vasculature by peptide homing.
The homing-peptide and proapoptotic-peptide fusion
Adipotide is a bipartite molecule. The first segment, the nine-amino-acid sequence CKGGRAKDC, serves as the targeting module. A 2004 paper by Kolonin, Saha, Chan, Pasqualini, and Arap used phage-display screening to identify this motif as one that homes selectively to the inner surface of blood vessels feeding white adipose tissue. The molecular receptor is prohibitin, a protein enriched on the luminal endothelium of adipose vasculature.
Subsequent work from Salameh, Daquinag, Staquicini, and colleagues in JCI Insight in 2016, extended in a 2022 diabetes paper by Gao, Daquinag, Yu, and Kolonin, showed that endothelial prohibitin-1 mediates bidirectional long-chain fatty acid transport in white and brown adipose tissue and that its loss in endothelial cells suppresses glucose utilization under high-fat-diet conditions which helps explain why prohibitin expression is concentrated in these depots and why it represents a tractable molecular address.
The second segment, D(KLAKLAK)2, is a proapoptotic effector: when delivered into a cell, this sequence disrupts mitochondrial membranes and triggers apoptosis through cytochrome c release, a mechanism characterized by Mai, Mi, Kim, Ng, and Robbins in Cancer Research in 2001, which showed that fusing a protein transduction domain to (KLAKLAK)2 triggered rapid apoptosis across tumor cell lines and, on direct intratumoral injection in C57BL/6 mice, shrank established MCA205 fibrosarcomas via mitochondrial membrane disruption and cytochrome c release. The two segments are joined by a short glycine linker.
Once the CKGGRAKDC domain binds prohibitin on adipose endothelium, the D(KLAKLAK)2 payload is internalized, the target cell undergoes apoptosis, and the blood vessels feeding that adipose depot are progressively ablated. Fat cells deprived of vascular supply then undergo secondary cell death.
Prohibitin as the adipose vascular address
The selectivity of adipotide depends on prohibitin's expression pattern. A 2013 review by Thuaud, Ribeiro, Nebigil, and Désaubry in Chemistry and Biology placed prohibitin in a broader context as a multifunctional scaffold protein implicated in mitochondrial integrity, cell signaling, and transcriptional regulation. A 2006 review by Mishra, Murphy L.C., and Murphy L.J. in the Journal of Cellular and Molecular Medicine established prohibitin's emerging roles in proliferation, apoptosis, and mitochondrial function. For adipotide's mechanism, what matters is the finding that prohibitin is specifically enriched at the vascular endothelium of white adipose tissue in obese animals, which gives the homing peptide its practical selectivity. Because the targeting relies on a receptor whose surface expression is tied to the metabolic state of the tissue, the biology is more nuanced than a purely anatomical address.
What the research shows
The foundational mouse study
In the 2004 Nature Medicine paper, the investigators treated diet-induced obese mice with the CKGGRAKDC-GG-D(KLAKLAK)2 peptidomimetic and observed approximately 30% body weight reduction over 28 days of treatment. The reduction was attributed to apoptosis of adipose vascular endothelium and subsequent fat-cell resorption, not to changes in food intake per se.
A follow-on study by Kim, Woods, Seeley, and colleagues published in diabetes in 2010 treated diet-induced obese C57BL/6 mice (n = 8 per group) with the CKGGRAKDC-GG-D(KLAKLAK)2 proapoptotic peptide at 150 μg subcutaneously over 27 days and reported significantly decreased cumulative energy intake and body weight in high-fat-diet-fed animals relative to vehicle controls (p < 0.05), with body weight of treated animals becoming statistically indistinguishable from lean low-fat-diet controls by day 27.
Notably, the same dose did not produce a conditioned taste aversion, indicating that reduced intake was not simply an illness-like aversive response; the rodent-only design and small cohort limit any inference to humans.
The same group Kim, Woods, and Seeley reporting in diabetes in 2012 (n = 8 per group), found that the same proapoptotic peptide produced rapid improvement in glucose tolerance in obese C57BL/6 mice by days 23 of treatment in a weight- and food-intake-independent manner (p < 0.05), alongside significantly reduced serum insulin and triglycerides (both p < 0.05) a finding that distinguishes the metabolic effects of the compound from simple fat loss and raises independent questions about how vascular disruption in adipose tissue affects systemic insulin signaling.
Both studies were conducted in mice only; no human data were generated.
The rhesus monkey study
The most consequential study of adipotide in a non-human primate model was published in Science Translational Medicine in 2011 by Barnhart, Christianson, Hanley, and colleagues. The study enrolled spontaneously obese rhesus macaques (n = 10 treated, n = 5 controls) a model that more closely approximates human obesity physiology than standard rodent models and administered adipotide at 0.43 mg/kg subcutaneously daily for 28 days, followed by a 28-day recovery period.
Treated primates lost approximately 10.6% of their body weight, with reductions in BMI and abdominal circumference and imaging-confirmed decreases in body fat (p < 0.0001), while untreated controls showed no change. Insulin resistance, assessed by fasting glucose and insulin measures, also improved in treated animals (p = 0.019). Importantly, the same paper described mild, dose-dependent, reversible renal tubular degeneration and regeneration accompanied by elevated serum creatinine that normalized post-treatment a signal that would shape the compound's subsequent development trajectory as discussed below.
The small cohort and short duration limit the strength of inferences that can be drawn about chronic-dosing safety.
Nanoparticle delivery and translational extensions
Follow-on work by Hossen, Kajimoto, Akita, Hyodo, and Harashima published in the Journal of Controlled Release in 2012 and extended in the same journal in 2013 explored whether nanoparticle delivery of the D(KLAKLAK)2 payload targeting CKGGRAKDC-bound endothelium could achieve comparable efficacy with a different toxicity profile. These studies are notable primarily as engineering responses to the kidney toxicity signal identified in the primate study: if the delivery vehicle could be modified, the therapeutic window might be shifted.
A 2013 paper by Azhdarinia, Daquinag, Tseng, and colleagues in Nature Communications adapted the same phage-display platform to identify a distinct brown-adipose-homing sequence (CPATAERPC) that selectively binds brown adipose vascular endothelium, using CKGGRAKDC as a white-fat control work that validated the broader vascular-address strategy across adipose depots. Daquinag, Tseng, Zhang, and colleagues published in Molecular Therapy in 2016 on using hunter-killer peptides to deplete adipose stromal cells and suppress tumor growth in mouse models, a translational extension of the adipotide concept into oncology.
An earlier 2015 paper in Cell Death and Differentiation by Daquinag, Tseng, Salameh, and colleagues demonstrated that depleting white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity in mice, establishing an adjacent targeting strategy from the same research lineage. The tumor-and-fat connection was further developed in a 2009 Cancer Research paper by Zhang, Daquinag, Traktuev, and colleagues showing that white adipose tissue cells are recruited by experimental tumors context that supports the rationale for extending adipotide-type platforms into oncology and cachexia.
The conceptual precursor: Anti-angiogenic weight loss
Adipotide's design was informed by an earlier conceptual demonstration. Rupnick, Panigrahy, Zhang, and colleagues published in PNAS in 2002 that anti-angiogenic agents including angiostatin and endostatin produced dose-dependent, reversible weight loss in ob/ob and diet-induced obese mice through vascular remodeling decreased endothelial proliferation and increased apoptosis in adipose tissue. Pasarica, Sereda, Redman, and colleagues confirmed in diabetes in 2009 that obese white adipose tissue is hypoxic and highly vascular-dependent. Together these findings established that the adipose vasculature is a legitimate pharmacological target and provided the intellectual context in which the PasqualiniArap group developed a receptor-targeted approach. The broader vascular-targeting anti-obesity strategy was subsequently reviewed by Daquinag, Zhang, and Kolonin in Trends in Pharmacological Sciences in 2011, which situates adipotide within the wider concept of ablating adipose vasculature as a therapeutic approach and discusses what would be required to translate the preclinical findings into clinical medicine.
Mechanistic confirmation of the KLAKLAK payload
Independent work has validated the mitochondrial mechanism of the D(KLAKLAK)2 domain outside the adipose context. A 2021 paper by Bahmani, Sharifzadeh, and colleagues in the Journal of Biomedical Physics and Engineering reported that a mitochondria-targeted D(KLAKLAK)2 peptide combined with gamma irradiation reduced cell viability and enhanced apoptosis in radio-resistant THP-1 human monocytic leukemia cells in vitro, and a 2013 PLoS One paper by Barbu, Shirazi, McGrath, and colleagues showed that a KLAKLAK-class antimicrobial peptidomimetic induces Mucorales cell death through mitochondria-mediated apoptosis. These reports corroborate the proposed mechanism: the D(KLAKLAK)2 sequence disrupts mitochondrial membranes in any cell type that internalizes it at sufficient concentration, which is why the selectivity of the upstream homing peptide matters so much for safety.
The kidney toxicity signal and why clinical development stalled
What the primate study found
The 2011 primate study reported dose-dependent changes to renal tubular morphology in adipotide-treated rhesus macaques. The histological findings were described as reversible upon cessation of treatment, meaning the kidney changes observed did not persist indefinitely after the compound was stopped. However, reversibility in a 28-day primate study does not characterize the full renal safety profile under chronic dosing conditions, at higher doses, or in humans. The kidney is the primary concern because the CKGGRAKDC peptide, once cleared from adipose binding sites, is processed renally, and the D(KLAKLAK)2 domain's mitochondria-disrupting activity is not inherently selective for adipose tissue if delivered at sufficient concentration to renal tubular cells.
What no published human data means in practice
As of April 2026, no completed peer-reviewed human efficacy or safety trial of adipotide has been published. A Phase 1 oncology trial in prostate cancer patients with obesity, announced by Arrowhead Research Corporation (then Ablaris Therapeutics) around 2012, was registered with ClinicalTrials.gov. That trial produced no peer-reviewed published results. The absence of published human data is itself informative: it means there is no characterized human renal toxicity threshold, no established tolerated dose range, no human pharmacokinetic profile, and no long-term safety signal in any human population. The preclinical data, though promising in its mechanistic specificity, cannot substitute for human Phase 1 safety data. Adipotide's safety in humans remains entirely uncharacterized.
Adipotide vs. GLP-1 receptor agonists: A mechanistic distinction
Adipotide is mechanistically unrelated to GLP-1 receptor agonists such as semaglutide and tirzepatide, and that distinction matters for understanding where each sits in the research landscape. GLP-1 receptor agonists work through incretin signaling: they bind receptors in the gut and brain that regulate appetite, gastric emptying, and glucose metabolism, producing weight loss primarily by reducing caloric intake and improving insulin dynamics.
The pivotal STEP 1 semaglutide trial, published in the New England Journal of Medicine in 2021 by Wilding, Batterham, Calanna, and colleagues, randomized 1,961 adults with overweight or obesity in a 2:1 ratio to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks and reported a mean body-weight change of −14.9% vs. −2.4% (treatment difference −12.4 percentage points; 95% CI, −13.4 to −11.5; p < 0.001), with nausea and diarrhea as the most common adverse events and treatment discontinuation for gastrointestinal events in 4.5% of the semaglutide group vs. 0.8% of placebo.
Tirzepatide, as a dual GIP/GLP-1 receptor agonist, was characterized by Willard, Douros, Gabe, and colleagues in JCI Insight in 2020 as acting through imbalanced receptor engagement that produces additive metabolic effects. A 2021 review by Tak and Lee in Current Obesity Reports situates both agents in a class of hormonal-signaling-based weight-loss pharmacotherapies, reporting placebo-subtracted 12-month weight reductions of 2.9% to 6.8% across FDA-approved agents in the broader anti-obesity category.
Adipotide's mechanism is entirely separate: it targets the structural vasculature of fat tissue, not appetite-regulating hormones or receptors. This means the two approaches address obesity biology at different levels and with different risk profiles. GLP-1 receptor agonists have cleared Phase 3 trials and are FDA-approved for specific indications. Adipotide has not. This comparison is offered for scientific context only; the compounds have fundamentally different regulatory statuses and evidence bases.
Regulatory and legal status
FDA classification
As of April 2026, adipotide is not FDA-approved for any indication. It has no FDA drug application on file, no approved label, and no classification as a compoundable bulk drug substance under 503A or 503B. The FDA's list of bulk drug substances that may present significant safety risks specifies certain compounds by name; adipotide is not on the list of approved compoundable substances. There is no legal compounding pathway for adipotide in the United States.
What this means practically
Products labeled as adipotide or FTPP sold through online vendors exist outside any regulatory framework. There is no FDA oversight of manufacturing, no verified identity of the compound, no guaranteed purity or potency, and no established safe dose for human use. Independent testing of research-peptide products sold online has consistently found contamination, incorrect concentrations, and misidentified compounds. The kidney toxicity signal identified in primate research adds a specific mechanistic reason for concern: obtaining a misdosed or contaminated product that carries D(KLAKLAK)2 activity is not a trivial risk. There is no legal pathway to obtain pharmaceutical-grade adipotide for human use in the United States, and no provider can legally prescribe it.
Safety: What is and is not known
Absence of human safety data
No peer-reviewed Phase 1 human safety data for adipotide exists. The standard information that characterizes a compound's human safety profile including maximum tolerated dose, pharmacokinetics, dose-limiting toxicities, and organ-specific effects at clinically relevant exposures is entirely absent for adipotide. The renal tubular changes observed in primates at doses that produced meaningful fat loss represent the primary known safety signal, but whether those findings translate to humans, and at what exposure level, is unknown. Extrapolating from a 28-day primate study to chronic human use is not scientifically defensible.
Risks from unregulated sources
The D(KLAKLAK)2 domain in adipotide disrupts mitochondrial membranes in any cell that internalizes it in sufficient quantity. The compound's safety in the primate model depended on the targeting selectivity of the CKGGRAKDC homing peptide. Unregulated products may have the wrong sequence, incorrect folding, or contaminants that alter biodistribution. A compound that fails to home specifically to adipose vasculature but retains the proapoptotic effector domain presents a different toxicity profile than what was studied preclinically. Purity verification and source integrity are not available for compounds sold outside regulated pharmaceutical channels.
Who should use adipotide
The short answer: no one, outside an IRB-approved clinical research study. Adipotide has no completed human efficacy or safety trial, no FDA approval, and no legal pathway for human use in the United States there is no population for whom use of this compound is supported by evidence. Products sold outside regulated pharmaceutical channels carry the additional risks of unverified identity, purity, and dose.
Several mechanistic considerations are of particular concern, drawn directly from the preclinical record. These are illustrative not a contraindication checklist, because there is no approved indication:
Pre-existing kidney disease or reduced renal function dose-dependent renal tubular toxicity was the primary safety signal in the Barnhart 2011 primate study at doses producing meaningful body-weight reduction Active or suspected cancer the prohibitin-targeting and vascular-ablation mechanism has not been characterized in humans with tumor vasculature that may also express prohibitin Pregnancy or breastfeeding no reproductive or developmental toxicology data exists Competitive athletes adipotide would fall under WADA Prohibited List category S0 (non-approved substances), independent of any health consideration
Which biomarkers are relevant if you are exploring peptide science?
Understanding baseline biology is a reasonable step for anyone interested in metabolic research compounds. For adipotide specifically, the proposed mechanism and the identified safety signal both point to specific, measurable markers worth tracking.
Creatinine and BUN (blood urea nitrogen): These are the primary serum markers of renal tubular function. Given that dose-dependent renal tubular changes were the principal safety finding in the Barnhart 2011 primate study, creatinine provides the most direct available proxy for monitoring renal status. Baseline values are necessary to interpret any subsequent change. Fasting insulin: The Kim 2012 Diabetes paper reported weight-independent glucose tolerance improvement in adipotide-treated mice, suggesting that adipose vascular disruption may have independent effects on insulin dynamics. A fasting insulin measurement establishes the baseline insulin-secretory and insulin-resistance picture that any weight-related intervention would alter. Fasting glucose and HbA1c: The primate study reported improved insulin resistance alongside weight loss. Fasting glucose captures acute glycemic status, while HbA1c provides a three-month average that reflects sustained glycemic patterns. Both are part of the metabolic picture that mechanistically connects adipose tissue, vascular function, and insulin sensitivity. High-sensitivity CRP (hs-CRP): Adipose tissue is a source of pro-inflammatory cytokines, and obesity-associated adipose expansion is associated with elevated systemic inflammation. Tracking hs-CRP provides a window into the inflammatory backdrop that vascular-targeting research compounds are studied against, and establishes whether baseline inflammation is a confounding variable. Fasting triglycerides: Fat tissue mass and lipolysis dynamics directly affect serum triglyceride levels. Triglycerides capture one of the most proximate biochemical correlates of adipose tissue turnover and provide context for metabolic research involving fat-loss compounds. A comprehensive metabolic panel: Because adipotide's safety concern is renal and the compound is metabolically active, a baseline metabolic panel including liver enzymes, electrolytes, and kidney function markers provides the full safety foundation that any investigation of this compound class would require.
For a curated view of which biomarkers are most informative in the context of metabolic health and weight loss, Superpower's best-biomarkers guide offers additional context organized around clinical utility.
When to take this seriously
If the biological question driving interest in adipotide is unwanted body fat, insulin resistance, or metabolic dysfunction, those are real and measurable problems with well-characterized clinical pathways. Endocrinologists, primary care physicians, and obesity medicine specialists evaluate the same underlying biology using markers that are well understood, FDA-approved pharmacological options supported by large-scale human trials, and lifestyle interventions with substantial clinical evidence. Establishing where your metabolic markers currently stand fasting insulin, glucose, HbA1c, and inflammatory markers gives any clinical conversation a concrete foundation. Objective data precedes good decisions.
That principle, measuring first and building from evidence, reflects Superpower's approach to preventive health: that understanding your biology is the precondition for every health decision worth making, whether you are evaluating established therapies or following the scientific literature on compounds that have not yet reached human trials.
IMPORTANT SAFETY INFORMATION
Adipotide is not approved by the FDA for any medical use. Research on this compound has been limited primarily to laboratory and animal studies, with little to no human clinical trial data available. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. Adipotide is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.
Safety profile in humans is unknown. The only available safety data comes from a 28-day rhesus macaque study by Barnhart and colleagues published in Science Translational Medicine in 2011 that identified dose-dependent, reversible renal tubular changes as the primary toxicity signal. No human pharmacokinetic data, no human maximum tolerated dose, and no human organ-specific toxicity profile have been published.
Adipotide should not be used by anyone outside an IRB-approved clinical research study. Mechanistic concerns of particular relevance: pre-existing kidney disease or reduced renal function (the primary preclinical toxicity signal); active or suspected cancer (uncharacterized effects on tumor vasculature); pregnancy or breastfeeding (no reproductive/developmental data); competitive athletes (WADA Prohibited List category S0).
Warnings: renal tubular toxicity (preclinical signal); unknown human dose-response relationship; no manufacturing oversight for products sold outside regulated pharmaceutical channels; contamination and misdosing risks from unregulated sources.
As of April 2026, no completed human efficacy or safety trials for adipotide have been published. Research interest does not constitute evidence of human safety or efficacy.
As of the 2026 WADA Prohibited List, adipotide would fall under category S0 (non-approved substances) and is prohibited in competition and out-of-competition for all sports.
FAQs
No. Adipotide is not FDA-approved for any indication and has no drug application on file. As of April 2026, it is not classified as a compoundable bulk drug substance under 503A or 503B, and there is no legal pathway to obtain it for human use in the United States.
Adipotide is not legally marketed for human use. It has no approved indication, no compounding status, and no regulatory authorization. Products sold online as "research use only" exist outside FDA oversight and carry no guarantee of identity, purity, or dose accuracy.
As of April 2026, no completed, peer-reviewed human efficacy or safety study of adipotide has been published. A Phase 1 oncology trial involving obese prostate cancer patients was registered around 2012 by Arrowhead Research Corporation but produced no peer-reviewed published results. The entire published evidence base consists of rodent studies and one rhesus macaque study.
The 2011 primate study in Science Translational Medicine found that spontaneously obese rhesus macaques lost approximately 11% of body weight over 28 days of adipotide treatment, with concurrent improvements in markers of insulin resistance. The same study also found dose-dependent, reversible changes to renal tubular morphology, which became the primary safety concern for clinical development.
The primary documented concern was the kidney toxicity signal identified in the primate study: dose-dependent renal tubular changes at doses that produced meaningful fat loss. The changes were described as reversible in the 28-day study, but the renal safety profile under chronic dosing in humans was never characterized because the Phase 1 trial that could have provided that data was never published. No peer-reviewed explanation for the termination of clinical development has been published by the sponsoring organization.
Adipotide and GLP-1 receptor agonists such as semaglutide and tirzepatide operate through entirely different mechanisms. GLP-1 receptor agonists modulate appetite and insulin secretion through hormonal signaling pathways that have been characterized in large-scale human trials. Adipotide targets the structural vasculature of white adipose tissue directly. It has not completed human trials. This comparison is offered for scientific context only; the compounds have fundamentally different regulatory statuses and evidence bases.
References
U.S. Food and Drug Administration. (n.d.). Certain bulk drug substances use compounding may present significant safety risks. https://fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks PubChem (National Library of Medicine). (n.d.). Adipotide. https://pubchem.ncbi.nlm.nih.gov/compound/163360068 Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., & Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature medicine, 10(6), 625-32. https://doi.org/10.1038/nm1048 Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., & Pasqualini, R. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nature medicine, 5(9), 1032-8. https://doi.org/10.1038/12469 Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardó-Vila, M., Giordano, R. J., Mintz, P. J., Ardelt, P. U., Yao, V. J., Vidal, C. I., Chen, L., Flamm, A., Valtanen, H., Weavind, L. M., Hicks, M. E., Pollock, R. E., Botz, G. H., Bucana, C. D., Koivunen, E., ... Pasqualini, R. (2002). Steps toward mapping the human vasculature by phage display. Nature medicine, 8(2), 121-7. https://doi.org/10.1038/nm0202-121 Salameh, A., Daquinag, A. C., Staquicini, D. I., An, Z., Hajjar, K. A., Pasqualini, R., Arap, W., & Kolonin, M. G. (2016). Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue. JCI insight, 1(10). https://doi.org/10.1172/jci.insight.86351 Gao, Z., Daquinag, A. C., Yu, Y., & Kolonin, M. G. (2022). Endothelial Prohibitin Mediates Bidirectional Long-Chain Fatty Acid Transport in White and Brown Adipose Tissues. Diabetes, 71(7), 1400-1409. https://doi.org/10.2337/db21-0972 Mai, J. C., Mi, Z., Kim, S. H., Ng, B., & Robbins, P. D. (2001). A proapoptotic peptide for the treatment of solid tumors. Cancer research, 61(21), 7709-12. https://pubmed.ncbi.nlm.nih.gov/11691780/ Thuaud, F., Ribeiro, N., Nebigil, C. G., & Désaubry, L. (2013). Prohibitin ligands in cell death and survival: mode of action and therapeutic potential. Chemistry & biology, 20(3), 316-31. https://doi.org/10.1016/j.chembiol.2013.02.006 Mishra, S., Murphy, L. C., & Murphy, L. J. (2006). The Prohibitins: emerging roles in diverse functions. Journal of cellular and molecular medicine, 10(2), 353-63. https://doi.org/10.1111/j.1582-4934.2006.tb00404.x Kim, D. H., Woods, S. C., & Seeley, R. J. (2010). Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight. Diabetes, 59(4), 907-15. https://doi.org/10.2337/db09-1141 Kim, D. H., Sartor, M. A., Bain, J. R., Sandoval, D., Stevens, R. D., Medvedovic, M., Newgard, C. B., Woods, S. C., & Seeley, R. J. (2012). Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium. Diabetes, 61(9), 2299-310. https://doi.org/10.2337/db11-1579 Barnhart, K. F., Christianson, D. R., Hanley, P. W., Driessen, W. H., Bernacky, B. J., Baze, W. B., Wen, S., Tian, M., Ma, J., Kolonin, M. G., Saha, P. K., Do, K. A., Hulvat, J. F., Gelovani, J. G., Chan, L., Arap, W., & Pasqualini, R. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science translational medicine, 3(108), 108ra112. https://doi.org/10.1126/scitranslmed.3002621 Hossen, M. N., Kajimoto, K., Akita, H., Hyodo, M., & Harashima, H. (2012). Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery. Journal of controlled release : official journal of the Controlled Release Society, 163(2), 101-10. https://doi.org/10.1016/j.jconrel.2012.09.002 Hossen, N., Kajimoto, K., Akita, H., Hyodo, M., & Harashima, H. (2013). A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. Journal of controlled release : official journal of the Controlled Release Society, 171(2), 104-12. https://doi.org/10.1016/j.jconrel.2013.07.013 Azhdarinia, A., Daquinag, A. C., Tseng, C., Ghosh, S. C., Ghosh, P., Amaya-Manzanares, F., Sevick-Muraca, E., & Kolonin, M. G. (2013). A peptide probe for targeted brown adipose tissue imaging. Nature communications, 4, 2472. https://doi.org/10.1038/ncomms3472 Daquinag, A. C., Tseng, C., Zhang, Y., Amaya-Manzanares, F., Florez, F., Dadbin, A., Zhang, T., & Kolonin, M. G. (2016). Targeted Proapoptotic Peptides Depleting Adipose Stromal Cells Inhibit Tumor Growth. Molecular therapy : the journal of the American Society of Gene Therapy, 24(1), 34-40. https://doi.org/10.1038/mt.2015.155 Daquinag, A. C., Tseng, C., Salameh, A., Zhang, Y., Amaya-Manzanares, F., Dadbin, A., Florez, F., Xu, Y., Tong, Q., & Kolonin, M. G. (2015). Depletion of white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity development. Cell death and differentiation, 22(2), 351-63. https://doi.org/10.1038/cdd.2014.148 Zhang, Y., Daquinag, A., Traktuev, D. O., Amaya-Manzanares, F., Simmons, P. J., March, K. L., Pasqualini, R., Arap, W., & Kolonin, M. G. (2009). White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer research, 69(12), 5259-66. https://doi.org/10.1158/0008-5472.CAN-08-3444 Rupnick, M. A., Panigrahy, D., Zhang, C. Y., Dallabrida, S. M., Lowell, B. B., Langer, R., & Folkman, M. J. (2002). Adipose tissue mass can be regulated through the vasculature. Proceedings of the National Academy of Sciences of the United States of America, 99(16), 10730-5. https://doi.org/10.1073/pnas.162349799 Ledoux, S., Queguiner, I., Msika, S., Calderari, S., Rufat, P., Gasc, J. M., Corvol, P., & Larger, E. (2008). Angiogenesis associated with visceral and subcutaneous adipose tissue in severe human obesity. Diabetes, 57(12), 3247-57. https://doi.org/10.2337/db07-1812 Daquinag, A. C., Zhang, Y., & Kolonin, M. G. (2011). Vascular targeting of adipose tissue as an anti-obesity approach. Trends in pharmacological sciences, 32(5), 300-7. https://doi.org/10.1016/j.tips.2011.01.004 Bahmani, T., Sharifzadeh, S., Tamaddon, G., Farzadfard, E., Zare, F., Fadaie, M., Alizadeh, M., Hadi, M., Ranjbaran, R., Mosleh-Shirazi, M. A., & Behzad-Behbahani, A. (2021). Mitochondrial Targeted Peptide (KLAKLAK). Journal of biomedical physics & engineering, 11(2), 229-238. https://doi.org/10.31661/jbpe.v0i0.905 Barbu, E. M., Shirazi, F., McGrath, D. M., Albert, N., Sidman, R. L., Pasqualini, R., Arap, W., & Kontoyiannis, D. P. (2013). An antimicrobial peptidomimetic induces Mucorales cell death through mitochondria-mediated apoptosis. PloS one, 8(10), e76981. https://doi.org/10.1371/journal.pone.0076981 Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D'Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 5(17). https://doi.org/10.1172/jci.insight.140532 Tak, Y. J., & Lee, S. Y. (2021). Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. Current obesity reports, 10(1), 14-30. https://doi.org/10.1007/s13679-020-00422-w
You should also read
Betaine HCL: Who Needs It for Low Stomach Acid
Rucking: Calorie Burn, Joint Impact, and Who It's Good For
William Maish, MD MBA MPH
Cortisol Face: What's Real and How to Test Your Own
William Maish, MD MBA MPH
PCOS and Belly Weight: The Hormones Behind It
William Maish, MD MBA MPH
Creatine Gummies vs. Powder: Which Form Actually Works?
William Maish, MD MBA MPH
Apple Cider Vinegar Gummies: Worth It or Just Hype?
William Maish, MD MBA MPH
Beef Tallow for Skin: Hype or Legitimate Remedy?
William Maish, MD MBA MPH
Mugwort Tea: What It Does and Who Should Avoid It
William Maish, MD MBA MPH
Does Okra Water Actually Do Anything?
William Maish, MD MBA MPH
Mushroom Coffee: Does It Actually Do Anything?
William Maish, MD MBA MPH
Red Light Therapy Panels: Which Wavelengths Actually Do Something
William Maish, MD MBA MPH
GABA for Sleep: The Blood-Brain Barrier Problem Nobody Mentions
William Maish, MD MBA MPH
Triphala: The Evidence Behind Ayurveda's Most Famous Formula
William Maish, MD MBA MPH
Sleepmaxxing: Which Practices Have Evidence Behind Them
William Maish, MD MBA MPH
Sleep Divorce: When Sleeping Apart Is Good for Your Health
William Maish, MD MBA MPH
Postbiotics: The Part of Gut Health Nobody Talks About
William Maish, MD MBA MPH
Oral Hyaluronic Acid: Does It Actually Improve Joints and Skin?
William Maish, MD MBA MPH
Zone 2 Running: How to Know You're Actually Training in Zone 2
William Maish, MD MBA MPH
Infrared Sauna Blankets vs. Regular Saunas: Are They Worth It?
William Maish, MD MBA MPH
NSDR: What Non-Sleep Deep Rest Does to Your Brain
William Maish, MD MBA MPH
Do Acupressure Mats Relieve Pain or Improve Sleep?
William Maish, MD MBA MPH
Does the Sleepy Girl Mocktail Help You Sleep?
William Maish, MD MBA MPH
Greens Powder: What You're Getting (and What It Can't Replace)
William Maish, MD MBA MPH
Probiotic Soda: Do the Bacteria Survive to Your Gut?
William Maish, MD MBA MPH
Emu Oil for Skin: What It Does and What It Doesn't
William Maish, MD MBA MPH
Ash Gourd Juice: Traditional Claims vs. What Science Shows
William Maish, MD MBA MPH
Psyllium Husk Capsules vs. Powder: Which Form Works Better?
William Maish, MD MBA MPH
Does Topical Magnesium Spray Absorb Through Skin?
William Maish, MD MBA MPH
What Somatic Exercises Do to Your Nervous System
William Maish, MD MBA MPH
Castor Oil Packs: What They Do and What They Don't
William Maish, MD MBA MPH
Raspberry Leaf Tea in Pregnancy: What the Evidence Says
William Maish, MD MBA MPH
NMN Supplements: What They Do to NAD+ (and Whether It Matters)
William Maish, MD MBA MPH
What Is the Winter Arc and Does It Hold Up?
William Maish, MD MBA MPH
Liquid Chlorophyll: What the Evidence Shows and What's Marketing
William Maish, MD MBA MPH
75 Soft vs. 75 Hard: Which Challenge Is Worth It?
William Maish, MD MBA MPH
Dihydroberberine vs. Berberine: Is the Upgrade Worth the Price?
William Maish, MD MBA MPH
Does Chromium Picolinate Reduce Cravings and Blood Sugar?
William Maish, MD MBA MPH
Weighted Vests: The Science Behind Bone Density and Calorie Burn
William Maish, MD MBA MPH
Nano Hydroxyapatite Toothpaste: Is It Better Than Fluoride?
William Maish, MD MBA MPH
Sea Moss Gel: What It Contains (and the Thyroid Risk)
William Maish, MD MBA MPH
Does Prebiotic Soda Actually Reach Your Gut?
William Maish, MD MBA MPH
Under-Desk Treadmills: How Much Walking at Work Changes Your Health
William Maish, MD MBA MPH
The Glucose Goddess Method: Which Hacks Hold Up to Science
William Maish, MD MBA MPH
Walking Pads: How Many Steps Actually Move the Needle?
William Maish, MD MBA MPH
Ox Bile Supplements: Who Needs Them After Gallbladder Removal
William Maish, MD MBA MPH
The Animal-Based Diet: What It Is and What the Research Shows
William Maish, MD MBA MPH
The Low Histamine Diet: Who Needs It and How to Know
William Maish, MD MBA MPH
Berberine Phytosome: More Effective Than Regular Berberine?
William Maish, MD MBA MPH
PEMF Mats: What They Do and When They Work
William Maish, MD MBA MPH
What Is Hurkle Durkle and Is Lying in Bed Good for You?
William Maish, MD MBA MPH
Redmond Real Salt: Does the Mineral Content Actually Matter?
William Maish, MD MBA MPH
Why Brown Noise Helps You Focus (and Sleep)
William Maish, MD MBA MPH
The Carnivore Diet: What Happens to Your Body After 30 Days
William Maish, MD MBA MPH
Magnesium L-Threonate: Does It Actually Cross the Blood-Brain Barrier?
William Maish, MD MBA MPH
Perifit Pelvic Floor Trainer: How It Works and Who Benefits
William Maish, MD MBA MPH
Benfotiamine vs. Regular B1: What's Different and When to Use It
William Maish, MD MBA MPH
Kefir Grains vs. Store-Bought Kefir: What's Different Probiotic-Wise?
William Maish, MD MBA MPH
Mouth Taping for Sleep: Who Should Try It and Who Should Skip It
William Maish, MD MBA MPH
Does Castor Oil Make Your Eyelashes Grow?
William Maish, MD MBA MPH
Celtic Sea Salt: Is It Worth Switching From Regular Salt?
William Maish, MD MBA MPH
Tart Cherry Juice: The Research on Sleep, Recovery, and Uric Acid
William Maish, MD MBA MPH
Blue Lotus Tea: What It Does to Your Brain and Whether It's Legal
William Maish, MD MBA MPH
Slippery Elm: What It Does in the Gut and What the Evidence Shows
William Maish, MD MBA MPH
Ceylon Cinnamon vs. Cassia: Why the Difference Matters
William Maish, MD MBA MPH
Seed Cycling for Hormones: What the Science Shows
William Maish, MD MBA MPH
Does Dry Brushing Move Lymph or Improve Skin?
William Maish, MD MBA MPH
Monk Mode: Does the Productivity Research Actually Back It Up?
William Maish, MD MBA MPH
The Raw Carrot Salad: What Ray Peat's Theory Gets Right and Wrong
William Maish, MD MBA MPH
Lion's Mane Powder vs. Capsules: Which Form Works Best?
William Maish, MD MBA MPH
Dopamine Detox: What Neuroscience Says (and What Actually Helps)
William Maish, MD MBA MPH
The Low Oxalate Diet: Who Needs It and Why
William Maish, MD MBA MPH
DIM Supplements: What the Estrogen-Metabolism Evidence Actually Shows
William Maish, MD MBA MPH
What 'California Sober' Means and the Health Trade-Offs
William Maish, MD MBA MPH
Chia Seed Water: Does It Help Weight Loss, Satiety, or Blood Sugar?
William Maish, MD MBA MPH
Nasal Dilators: Internal vs. External Which Works Better?
William Maish, MD MBA MPH
Do Nasal Strips Reduce Snoring or Help Athletic Performance?
William Maish, MD MBA MPH
The Adrenal Cocktail: What Each Ingredient Actually Does
William Maish, MD MBA MPH
Urolithin A: The Mitophagy Compound Your Gut May Not Be Making
William Maish, MD MBA MPH
The Dopamine Menu: A Smarter Alternative to Detoxing
William Maish, MD MBA MPH
Apigenin for Sleep: What This Chamomile Compound Does
William Maish, MD MBA MPH
Butyrate Supplements: Worth Taking or Just Feed Your Gut?
William Maish, MD MBA MPH
Do Compression Boots Speed Up Recovery?
William Maish, MD MBA MPH
Shatavari: Evidence for Menopause, Lactation, and Female Health
William Maish, MD MBA MPH
Inulin Powder: Prebiotic Benefits, Gas Risk, and the Right Dose
William Maish, MD MBA MPH
Cycle Syncing: What Your Hormones Do Each Phase of the Month
William Maish, MD MBA MPH
Oatzempic: What It Is and Why It's Nothing Like Ozempic
William Maish, MD MBA MPH
Total T4: The Thyroxine Pool Your Binding Proteins Can Inflate
William Maish, MD MBA MPH
Glycation Gap: When Your HbA1c and Glucose Disagree
William Maish, MD MBA MPH
eGFR (Estimated Glomerular Filtration Rate): Your Kidneys' Filtration Speedometer
William Maish, MD MBA MPH
Fructosamine: A Two-to-Three-Week Window on Your Blood Sugar
William Maish, MD MBA MPH
Ferritin-to-Albumin Ratio (FAR): What a High Score Says About Inflammation
William Maish, MD MBA MPH
Vitamin C, Decoded: Why the Sample Matters as Much as the Result
William Maish, MD MBA MPH
TPO Antibodies: The Thyroid Signal That Shows Up Years Early
William Maish, MD MBA MPH
Free Androgen Index (FAI): The Bioavailable Testosterone Your Total Count Hides
William Maish, MD MBA MPH
Ferritin: The Iron Marker That Drops Before Anemia Shows
William Maish, MD MBA MPH
hCG: Fertility, Testosterone Support, and How This Glycoprotein Hormone Works
William Maish, MD MBA MPH
Tretinoin: A Prescription Retinoid for Acne, Photoaging, and Hyperpigmentation
William Maish, MD MBA MPH
Metformin: An Insulin Sensitizer Used for Blood Sugar and Longevity Research
William Maish, MD MBA MPH
Enclomiphene: A Selective Estrogen Receptor Modulator for Testosterone Support
William Maish, MD MBA MPH
Low-Dose Naltrexone: An Off-Label Approach to Immune Modulation and Chronic Pain
William Maish, MD MBA MPH
Built by the world’s top doctors and scientists
Dr Anant Vinjamoori, MD
Chief Longevity Officer, Superpower
Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in WSJ, Forbes, and Fortune.
Learn more
Dr Leigh Erin Connealy, MD
Clinician & Founder of The Centre for New Medicine
Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.
Learn more
Dr Robert Lufkin
UCLA Medical Professor, NYT Bestselling Author
A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.
Learn more
Dr Abe Malkin
Founder & Medical Director of Concierge MD
Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company
Learn more
Medical Advisory Board
Medical Advisory Board
1 / 3
Your membership starts here
Annual 100+ biomarker panel
Data dashboard and digital twin
Upload past labs and connect wearables
Personalized health protocol
24/7 care team access
AI companion for all health questions
Marketplace with additional solutions
$199
/year*
Billed annually
HSA/ FSA eligible
Cancel anytime
Results in a week
* Pricing may vary for members in New York and New Jersey